

Ref. No.: LASA/SE/17-18/028

Tuesday January 2, 2018

To, Corporate Services Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department <b>National Stock Exchange of India Limited</b> “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir,

**Sub. : Press Release**

With reference to the above subject, please find enclosed Press release of our Company titled “New CEP application filed for VET API range of product with EDQM – Europe”.

Request you to take the same on record and acknowledge receipt.

Thanking you,

Yours Truly,

**For LASA SUPERGENERICS LIMITED**



**HITESH WADHWANI**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**  
(M. NO. A43914)  
Encl: as above.



## **Media Release**

### **New CEP application filed for VET API range of product with EDQM – Europe**

**Mumbai, January 2, 2018:** Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, announced that the Company has filed new CEP application for VET API product with EDQM (European Directorate for the Quality of Medicines) - Europe.

#### **Management Comments:**

Commenting on the recent development, Mr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

*“We are very pleased to inform that the Company has filed new CEP application for VET API product with EDQM (European Directorate for the Quality of Medicines) – Europe, for which, as a pre requisite, the Company has already cleared EU audit successfully. The Company will benefit preapprovals for larger sale of its product in the European Market. With this achievement, domestic players which export formulations to European market will also form a part of additional business. This is another important step towards laying a strong foundation and meeting our desired targets. The Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.*

*I would like to thank the entire team of ‘LASA’ for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength.”*

#### **About Lasa Supergenerics Limited:**

Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specializes in ‘catalyst chemistry’ and manufactures anthelmintic / veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs



## Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: [www.lasalabs.com](http://www.lasalabs.com)

For any Investor Relations query, please contact:

<b>Dr. Omkar Herlekar</b> <b>Chairman &amp; MD</b> <b>Lasa Supergenerics Limited</b> Email: <a href="mailto:investor@lasalabs.com">investor@lasalabs.com</a>	<b>Amit Sharma</b> <b>Bridge Investor Relations Pvt. Ltd.</b> Phone: +91-22-26873003 Email: <a href="mailto:amit@bridge-ir.com">amit@bridge-ir.com</a>
---	---

**Note:** *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*